TABLE 2.
Patient outcomes
| Group A (n=17) | Group B (n=20) | P | |
|---|---|---|---|
| Primary end point | 9 (53) | 12 (60) | 0.66 |
| Death at 30 days | 8 (47) | 6 (30) | 0.85 |
| Hospital mortality | 8 (47) | 10 (50) | 0.85 |
| Stroke | 0 (0) | 3 (15) | 0.09 |
| Reinfarction | 0 (0) | 0 (0) | |
| Severe acute renal failure | 1 (6) | 3 (15) | 0.62 |
| Hospital stay, days, mean | 14 | 14 | |
| Discharge at 30 days | 3 (18) | 9 (45) | 0.19 |
| Bleeding | |||
| TIMI major bleeding | 2 (12) | 2 (10) | 0.86 |
| TIMI minor or minimal bleeding | 5 (29) | 1 (5) | <0.05 |
| Transfusion | 6 (35) | 2 (10) | 0.07 |
| TIMI flow pre-percutaneous coronary intervention, n | |||
| 0 | 9 | 13 | 0.28 |
| 1 | 0 | 2 | |
| 2 | 5 | 2 | |
| 3 | 3 | 3 | |
| TIMI flow post-percutaneous coronary intervention, n | |||
| 0 | 0 | 3 | <0.05 |
| 1 | 2 | 0 | |
| 2 | 0 | 4 | |
| 3 | 14 | 12 | |
Data presented as n (%) unless otherwise indicated. Bold values indicate statistical significance. Group A Routine preprocedural abciximab group; Group B Standard therapy group; TIMI Thrombolysis in myocardial infarction bleeding criteria